Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy

被引：10

作者：

Aghamiri, Shahin ^{[1
,2
]}

Raee, Pourya ^{[3
]}

Shahmohamadnejad, Shiva ^{[4
]}

Shabani, Sasan ^{[5
]}

Ghorbani, Jaber ^{[6
]}

Sameni, Marzieh ^{[7
]}

Ebrahimi, Mohammad Taha ^{[7
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran 193954818, Iran

[2] Shahid Beheshti Univ Med Sci, Cellular & Mol Biol Res Ctr, Tehran, Iran

[3] Shahid Beheshti Univ Med Sci, Sch Med, Dept Biol & Anat Sci, Tehran, Iran

[4] Univ Tehran Med Sci, Dept Biochem, Fac Med, Tehran, Iran

[5] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran

[6] Univ Tehran Med Sci, Sch Med, Dept Microbiol, Tehran, Iran

[7] Shahid Beheshti Univ Med Sci, Dept Med Biotechnol, Sch Adv Technol Med, Tehran, Iran

来源：

CURRENT PHARMACEUTICAL BIOTECHNOLOGY | 2022年 / 23卷 / 04期

关键词：

Prostate cancer; nanoparticles; siRNA; drug delivery systems; multidrug resistance; combination therapy; CELL-ADHESION MOLECULE; SMALL INTERFERING RNA; MULTIDRUG-RESISTANCE; CO-DELIVERY; DRUG-DELIVERY; ANTISENSE OLIGONUCLEOTIDE; TARGETED DELIVERY; CATIONIC NANOBUBBLES; ANTICANCER DRUGS; PHASE-I;

D O I：

10.2174/1389201022666210615123211

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The critical problems of conventional prostate cancer therapeutic strategies like nonspecific toxicity and multi-drug resistance prompted the development and application of countless nanoparticle-based siRNA therapeutics. Unfortunately, siRNA-based therapeutics suffer from the lack of safe and effective delivery systems, immune system stimulation, poor knowledge of nano-bio interactions, and limitations concerning designing, manufacturing, clinical translation, and commercialization. In this review, we provide cutting-edge advances in nanoparticle-mediated siRNA delivery carriers like polymeric systems, lipid systems, specific systems, and rigid nanoparticles for the treatment of prostate cancer. Moreover, co-delivery of conventional chemotherapy drugs with siRNA as a revolutionary robust strategy for prostate cancer combinational therapy is completely covered.

引用

页码：579 / 593

页数：15

共 129 条

[1] Bcl-2-regulated apoptosis: mechanism and therapeutic potential [J].